CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study of Dasatinib added to Standard Chemotherapy for Relapsed/Refractory Ph+ALL

Grant

Date/time Interval

  • June 30, 2017 - July 1, 2018

    • Awarded By

    Total Award Amount

  • 0.00

    • Direct Costs

  • 0.00

    • Sponsor Award Id

    • Contributor

  • Matthew Kutny M.D.   Principal Investigator